ADRB2 and cardiovascular disorder: Thus, pepducins that function as ligands for intracellular allosteric sites of β2-AR and have a wide range of pharmacological activity are good candidates for the development of new drugs for the treatment of cardiovascular diseases [234,429,430,431].